Reception of immunopotentiator licopid at carrying out antihelicobacter therapy of the first choice
To determine the percent of H.pylori (Hp) eradication at carrying out eradication therapies of the first choice on a background of reception licopid. Randomly selected 101 patients with duodenal ulcer were examined in prospective comparative study. Eradication therapy is carried out at 101 patients with duodenal ulcer associated with H.pylori (middle age 43.7 ± 13.4 years (18-65 years), ratio of men and women - 67/34). Diagnostics H.pylori in a mucous membrane of a stomach and duodenum were carried out by Giemsa and rapid urease test (Rohm Pharma, AMA) before treatment and in 6-8 weeks after the ending of treatment and a cancellation of all drugs. Regions of gastric metaplasia (GM) of duodenum were confirmed by periodic acid-Schiff and alcian blue (Serva) staining (pH 1.0; 2.5). All patients have been divided into 3 groups, according to protocol of treatment: omeprazole 0.02 g + clarithromycin 0.5 g + amoxicillin 1.0 g BID, within 7 days (ÎCÀ7; n=33) and 14 days (ÎCÀ14; n=34); omeprazole 0.02 g + clarithromycin 0.5 g + amoxicillin 1.0 g BID within 7 days, and licopid 0.001 g QID within 10 days, (ÎCÀ7L10; n=34). The percent of H.pylori eradication: ÎCÀ7 – 81.8% (ITT) and 87.1% (PP), ÎCÀ14 – 82.4% (ITT) and 93.3% (PP), ÎCÀ7L10 – 88.2% (ITT) and 93.8% (PP). Quantity of side effects: ÎCÀ7 – 6.1%, ÎCÀ14 – 17.6% (have stopped treatment of 5.9%), ÎCÀ7L10 – 5.9%. Cost of protocols of treatment: ÎCÀ7 – 32 $, ÎCÀ14 – 64 $, ÎCÀ7L10 – 44 $. Reception of licopid at carrying out classical eradication therapy of the first choice for 7 days elevate the percent of H.pylori eradication on 6.4% (ITT) and 6.7% (PP), without increase in number of side effects. At H.pylori-positive patients with duodenal ulcer licopid is expedient to appoint at carrying out 7 day schemes of eradication therapies, as alternative 14 day schemes of treatment.